---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-311229"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:04:12.456942+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics Q3 net loss $2.9M; durable remissions with agenT-797, cash runway through 2026

## Summary
- Net loss $2.9M ($0.65/share) in Q3 2025 vs $1.8M ($0.46) in Q3 2024.
- Cash $14.3M at quarter-end; raised $1.2M post-quarter; runway extended through 2026.
- Clinical data: durable complete remissions >2 years in refractory cancers; no Grade 3+ CRS/neurotoxicity.
- Launching Phase 1 GvHD study with UW-Madison, funded by NIH and philanthropy.
- Appointed Dr. Terese Hammond as Head of Inflammatory and Pulmonary Diseases, Dr. Holcomb to Board.

## SEC filing metadata
- accession: 0001193125-25-311229
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/0001193125-25-311229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-20251114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-311229
- JSON: https://secwatch.observer/filing/0001193125-25-311229.json
- Plain text: https://secwatch.observer/filing/0001193125-25-311229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.